Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov 13;8(11):499.
doi: 10.3390/biomedicines8110499.

Effects of Pitavastatin, Atorvastatin, and Rosuvastatin on the Risk of New-Onset Diabetes Mellitus: A Single-Center Cohort Study

Wei-Ting Liu  1 , Chin Lin  2   3   4 , Min-Chien Tsai  5 , Cheng-Chung Cheng  6 , Sy-Jou Chen  7   8 , Jun-Ting Liou  6 , Wei-Shiang Lin  6 , Shu-Meng Cheng  6 , Chin-Sheng Lin  6 , Tien-Ping Tsao  6   9
Affiliations

Effects of Pitavastatin, Atorvastatin, and Rosuvastatin on the Risk of New-Onset Diabetes Mellitus: A Single-Center Cohort Study

Wei-Ting Liu et al. Biomedicines. .

Abstract

Statins constitute the mainstay treatment for atherosclerotic cardiovascular disease, which is associated with the risk of new-onset diabetes mellitus (NODM). However, the effects of individual statins on the risk of NODM remain unclear. We recruited 48,941 patients taking one of the three interested statins in a tertiary hospital between 2006 and 2018. Among them, 8337 non-diabetic patients taking moderate-intensity statins (2 mg/day pitavastatin, 10 mg/day atorvastatin, and 10 mg/day rosuvastatin) were included. The pitavastatin group had a higher probability of being NODM-free than the atorvastatin and rosuvastatin groups during the 4-year follow-up (log-rank test: p = 0.038). A subgroup analysis revealed that rosuvastatin had a significantly higher risk of NODM than pitavastatin among patients with coronary artery disease (CAD) (adjusted HR [aHR], 1.47, 95% confidence interval [CI], 1.05-2.05, p = 0.025), hypertension (aHR, 1.26, 95% CI, 1.00-1.59, p = 0.047), or chronic obstructive pulmonary disease (COPD) (aHR, 1.74, 95% CI, 1.02-2.94, p = 0.04). We concluded that compared with rosuvastatin, reduced diabetogenic effects of pitavastatin were observed among patients treated with moderate-intensity statin who had hypertension, COPD, or CAD. Additional studies are required to prove the effects of different statins on the risk of NODM.

Keywords: atherosclerotic cardiovascular disease; new-onset diabetes mellitus; statins.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Flowchart of study population enrollment based on the inclusion and exclusion criteria. DM: diabetes mellitus; N: number of patients.
Figure 2
Figure 2
Kaplan–Meier plot of three statin groups for new-onset diabetes mellitus (NODM)-free probabilities curve. The NODM-free probabilities were significantly higher in the pitavastatin group than in the atorvastatin and rosuvastatin groups (log-rank test: p = 0.038) (a) and the group of combined atorvastatin and rosuvastatin (log-rank test: p = 0.043) (b).
See this image and copyright information in PMC

References

    1. Mach F., Baigent C., Catapano A.L., Koskinas K.C., Casula M., Badimon L., Chapman M.J., De Backer G.G., Delgado V., Ference B.A., et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Eur. Heart J. 2019;41:111–188. doi: 10.1093/eurheartj/ehz455. - DOI - PubMed
    1. Grundy S.M., Stone N.J., Bailey A.L., Beam C., Birtcher K.K., Blumenthal R.S., Braun L.T., de Ferranti S., Faiella-Tommasino J., Forman D.E., et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139:e1082–e1143. doi: 10.1161/CIR.0000000000000625. - DOI - PMC - PubMed
    1. Baigent C., Blackwell L., Emberson J., Holland L.E., Reith C., Bhala N., Peto R., Barnes E.H., Keech A., Simes J., et al. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670–1681. doi: 10.1016/s0140-6736(10)61350-5. - DOI - PMC - PubMed
    1. Adhyaru B.B., Jacobson T.A. Safety and efficacy of statin therapy. Nat. Rev. Cardiol. 2018;15:757–769. doi: 10.1038/s41569-018-0098-5. - DOI - PubMed
    1. Ridker P.M., Danielson E., Fonseca F.A., Genest J., Gotto A.M., Jr., Kastelein J.J., Koenig W., Libby P., Lorenzatti A.J., MacFadyen J.G., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 2008;359:2195–2207. doi: 10.1056/NEJMoa0807646. - DOI - PubMed

LinkOut - more resources